CPSE:NOVO BPharmaceuticals
Novo Nordisk (CPSE:NOVO B) Is Up 5.2% After Rybelsus Wins EU Cardiovascular Label Update – Has The Bull Case Changed?
Earlier this week, Novo Nordisk announced that the European Medicines Agency approved an updated Rybelsus label to reflect cardiovascular benefits in type 2 diabetes, following the results of the SOUL trial presented at the European Association for the Study of Diabetes 2025 Congress in Vienna.
This approval positions Rybelsus as the first oral GLP-1 therapy in the EU with proven cardiovascular benefit, potentially expanding its clinical reach among patients with type 2 diabetes at increased...